Koizumi H, Gomi F, Tsujikawa A, Honda S, et al. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial. Graefes Arch Clin Exp Ophthalmol 2024 Mar 14. doi: 10.1007/s00417-024-06377.
PMID: 38483611